Tenascin-C as a prognostic biomarker in osteosarcoma?

Chinese Medical Journal

Volumn 122, Issue 22, 2009, Pages 2737-2743

  Xiong, Wei ^a   Niu, Peng Yan ^a   Zhu, Wen Tao ^a   Chen, Jing ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Metastasis; Osteosarcoma; Tenascin C

Indexed keywords

MESSENGER RNA; TENASCIN; TUMOR MARKER;

ARTICLE; CANCER CELL CULTURE; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNINDEXED SEQUENCE;

ADOLESCENT; ADULT; BONE NEOPLASMS; CELL LINE, TUMOR; CHILD; FEMALE; HUMANS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOSARCOMA; PROGNOSIS; RNA, MESSENGER; TENASCIN;

EID: 73449129676     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.22.012     Document Type: Article

References (42)

1. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20: 776-790.
2. Hauben EI, Weeden S, Pringle J, Van Marck EA, Hogendoorn PC. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer 2002; 38: 1218-1225.
3. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-799.
4. Lev DC, Kiriakova G, Price JE. Selection of more aggressive variants of the gI101A human breast cancer cell line: a model for analyzing the metastatic phenotype of breast cancer. Clin Exp Metastasis 2003; 20: 515-523.
5. Jia SF, Worth LL, Kleinerman ES. A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin Exp Metastasis 1999; 17: 501-506.
6. Nakano T, Tani M, Ishibashi Y, Kimura K, Park YB, Imaizumi N, et al. Biological properties and gene expression associated with metastatic potential of human osteosarcoma. Clin Exp Metastasis 2003; 20: 665-674.
7. Shi XB, Chen AM, Cai XH, Guo FJ, Liao GN, Ma D. Establishment and characterization of cell sublines with high and low metastatic potential derived from human osteosarcoma. Chin Med J 2005; 118: 687-690.
8. Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007; 356: 217-226.
9. Melillo G, Semenza GL. Meeting report: exploiting the tumor microenvironment for therapeutics. Cancer Res 2006; 66: 4558-4460.
10. Bornstein P, Sage EH. Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol 2002; 14: 608-616.
11. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004; 5: 816-826.
12. Pupa SM, Menard S, Forti S, Tagliabue E. New insights into the role of extracellular matrix during tumor onset and progression. J Cell Physiol 2002; 192: 259-267.
13. Chiquet-Ehrismann R, Chiquet M. Tenascins: regulation and putative functions during pathological stress. J Pathol 2003; 200: 488-499.
14. Ioachim E, Michael M, Stavropoulos NE, Kitsiou E, Salmas M, Malamou-Mitsi V. A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma. BJU Int 2005; 95: 655-659.
15. Ishiwata T, Takahashi K, Shimanuki Y, Ohashi R, Cui R, Takahashi F, et al. Serum tenascin-C as a potential predictive marker of angiogenesis in non-small cell lung cancer. Anticancer Res 2005; 25: 489-495.
16. Iskaros BF, Tanaka KE, Hu X, Kadish AS, Steinberg JJ. Morphologic pattern of tenascin as a diagnostic biomarker in colon cancer. J Surg Oncol 1997; 64: 98-101.
17. Kaarteenaho-Wiik R, Soini Y, Pollanen R, Paakko P, Kinnula VL. Over-expression of tenascin-C in malignant pleural mesothelioma. Histopathology 2003; 42: 280-291.
18. Korshunov A, Golanov A, Ozerov S, Sycheva R. Prognostic value of tumor-associated antigens immunoreactivity and apoptosis in medulloblastomas. An analysis of 73 cases. Brain Tumor Pathol 1999; 16: 37-44.
19. Pilch H, Schaffer U, Schlenger K, Lautz A, Tanner B, Hockel M, et al. Expression of tenascin in human cervical cancer - association of tenascin expression with clinicopathological parameters. Gynecol Oncol 1999; 73: 415-421.
20. Suwiwat S, Ricciardelli C, Tammi R, Tammi M, Auvinen P, Kosma VM, et al. Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res 2004; 10: 2491-2498.
21. Tokes AM, Hortovanyi E, Csordas G, Kulka J, Mozes G, Hatalyak A, et al. Immunohistochemical localisation of tenascin in invasive ductal carcinoma of the breast. Anticancer Res 1999; 19: 175-179.
22. Zamecnik J, Chanova M, Tichy M, Kodet R. Distribution of the extracellular matrix glycoproteins in ependymomas - an immunohistochemical study with follow-up analysis. Neoplasma 2004; 51: 214-222.
23. Zirbes TK, Baldus SE, Moenig SP, Schmitz K, Thiele J, Holscher AH, et al. Tenascin expression in gastric cancer with special emphasis on the WHO-, Lauren-, and Goseki-classifications. Int J Mol Med 1999; 4: 39-42.
24. Lewin A, Grieve IC. Grouping Gene Ontology terms to improve the assessment of gene set enrichment in microarray data. BMC Bioinformatics 2006; 7: 426.
25. Assoian RK, Marcantonio EE. The extracellular matrix as a cell cycle control element in atherosclerosis and restenosis. J Clin Invest 1996; 98: 2436-2439.
26. Damsky CH, Werb Z. Signal transduction by integrin receptors for extracellular matrix: cooperative processing of extracellular information. Curr Opin Cell Biol 1992; 4: 772-781.
27. Juliano RL, Haskill S. Signal transduction from the extracellular matrix. J Cell Biol 1993; 120: 577-585.
28. Stupack DG, Cheresh DA. Get a ligand, get a life: integrins, signaling and cell survival. J Cell Sci 2002; 115: 3729-3738.
29. Tanaka M, Yamazaki T, Araki N, Yoshikawa H, Yoshida T, Sakakura T, et al. Clinical significance of tenascin-C expression in osteosarcoma: tenascin-C promotes distant metastases of osteosarcoma. Int J Mol Med 2000; 5: 505-510.
30. Mackie EJ, Murphy LI. The role of tenascin-C and related glycoproteins in early chondrogenesis. Microsc Res Tech 1998; 43: 102-110.
31. Brunner A, Mayerl C, Tzankov A, Verdorfer I, Tschorner I, Rogatsch H, et al. Prognostic significance of tenascin-C expression in superficial and invasive bladder cancer. J Clin Pathol 2004; 57: 927-931.
32. Orend G, Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett 2006; 244: 143-163.
33. Puente Navazo MD, Valmori D, Ruegg C. The alternatively spliced domain TnFnIII A1A2 of the extracellular matrix protein tenascin-C suppresses activation-induced T lymphocyte proliferation and cytokine production. J Immunol 2001; 167: 6431-6440.
34. Garraway LA, Sellers WR. Lineage dependency and lineage-survival oncogenes in human cancer. Nat Rev Cancer 2006; 6: 593-602.
35. Mackie EJ, Ramsey S. Modulation of osteoblast behaviour by tenascin. J Cell Sci 1996; 109 (Pt 6): 1597-1604.
36. Mintz MB, Sowers R, Brown KM, Hilmer SC, Mazza B, Huvos AG, et al. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res 2005; 65: 1748-1754.
37. Helfrich MH, Nesbitt SA, Dorey EL, Horton MA. Rat osteoclasts adhere to a wide range of RGD (Arg-Gly-Asp) peptide-containing proteins, including the bone sialoproteins and fibronectin, via a beta 3 integrin. J Bone Miner Res 1992; 7: 335-343.
38. Man TK, Chintagumpala M, Visvanathan J, Shen J, Perlaky L, Hicks J, et al. Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res 2005; 65: 8142-8150.
39. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006; 10: 529-541.
40. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10: 515-527.
41. Nguyen DX, Massague J. Genetic determinants of cancer metastasis. Nat Rev Genet 2007; 8: 341-352.
42. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005; 8: 393-406.